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Summary
Objective: To investigate whether two different multiphasic implants could initiate and sustain repair of osteochondral defects in rabbits. The
implants address the malleable properties of cartilage while also addressing the rigid characteristics of subchondral bone.
Design: The bone region of both devices consisted of D, DeL, L-polylactic acid invested with hyaluronan (HY). The cartilage region of the ﬁrst
device was a polyelectrolytic complex (PEC) hydrogel of HY and chitosan. In the second device the cartilage region consisted of type I
collagen scaffold. Eighteen rabbits were implanted bilaterally with a device, or underwent defect creation with no implant. At 24 weeks,
regenerated tissues were evaluated grossly, histologically and via immunostaining for type II collagen.
Results: PEC devices induced a signiﬁcantly better repair than untreated shams. Collagen devices resulted in a quality of repair close to that
of the PEC group, although its mean repair score (19.0G 4.2) did not differ signiﬁcantly from that of the PEC group (20.4G 3.7) or the shams
(16.5G 6.3). The percentage of hyaline-appearing cartilage in the repair was highest with collagen implants, while the degree of bonding of
repair to the host, structural integrity of the neocartilage, and reconstitution of the subchondral bone was greatest with PEC devices. Cartilage
in both device-treated sites stained positive for type II collagen and GAG.
Conclusions: Both implants are capable of maintaining hyaline-appearing tissue at 24 weeks. The physicochemical region between the
cartilage and bone compartments makes these devices well suited for delivery of different growth factors or drugs in each compartment, or
different doses of the same factor. It also renders these devices excellent vehicles for chondrocyte or stem cell transplantation.
ª 2005 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.





Healing of clinically signiﬁcant articular cartilage defects
commonly results in a ﬁbrocartilaginous repair1. Such
repairs are biochemically and biomechanically different
from normal hyaline cartilage and are unable to withstand
repetitive load-bearing conditions at the articular surface2.
Articular cartilage is frequently subjected to osteoarthritic
degeneration over time, beginning as surface ﬁbrillation and
ﬁssuring while progressing to erosion and exposure of the
subchondral bone3,4.
Over 600,000 procedures are performed in the United
States each year to repair damaged knee cartilage. The
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Received 5 August 2004; revision accepted 18 April 2005.79majority of these are repeat procedures, underscoring the
ineffectiveness of current surgical treatment options5.
Therapeutic attempts to repair or restore articular cartilage
face intrinsic biological constraints; the tissue is avascular
and lacks an appropriate population of repair or progenitor
cells. Despite the bleak prognosis for repair, recent cartilage
regeneration techniques based on tissue engineering
principles may offer promise for treatment of human
articular cartilage defects6. Autologous chondrocyte trans-
plantation and other new methods have reported generally
good results in treating osteochondritis dissecans as well as
osteochondral defects in various animal models7e9.
Researchers have reported lasting repair of full-thickness
lesions exclusively in instances where the subchondral
bone component of the defect has been regenerated and
the entire defect’s normal gross architecture and state of
organization restored10,11. These observations suggest that
the quality of underlying subchondral bone may affect
regeneration and longevity of articular cartilage repair
tissue11. Thus, bone replacement must be considered in
tandem with articular cartilage regeneration in any attempt8
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results in a lasting hyaline resurfacing.
Various three-dimensional (3-D) scaffolds have been
used as substrates to facilitate or promote articular cartilage
repair12e17. Many of these efforts, however, have employed
matrices composed of monolithic gross architectures that
do not confer tissue-speciﬁc bioenvironments for both
cartilage and bone repair processes. Chondrocytes must
be protected from intimate contact with blood vessel
formation18,19. Osteoblasts require vascularization20e23.
These two tissues consider the setting of the other to be
developmentally hostile, yet they must simultaneously
mature juxtaposed and form a competent bond. This
biologic constraint is non-negotiable and illustrates the
complicated requirements for articular cartilage regenera-
tion and repair. Clinical strategies that take into account the
disparate wound healing requirements of the tissues
involved may be more likely to produce favorable results.
Ideally, the appropriate biophysical conditions and environ-
ment for both tissues would be present to facilitate and
enhance proper cellular activities.
The object of the present study was to investigate
whether two different multiphasic implants could initiate
regeneration and repair of osteochondral defects in rabbits.
The implants were designed to address the malleable
properties of the cartilage region while also addressing the
rigid characteristics of the subchondral bone region. The
two tissue-speciﬁc devices being studied differed only in
their superﬁcial layer or ‘‘articular cartilage fabric’’ (ACF).
The ﬁrst ACF was composed of hyaluronan (HY) and
chitosan (CT) reacted as a polyelectrolytic complex
(HYeCT-PEC). In its dry form, the HYeCT-PEC fabric is
an open-cell matrix (Fig. 1). When fully hydrated, this dry
matrix resolves into a malleable hydrogel. The ACF of the
second device consisted of type I collagen, processed into
a 3-D malleable substratum (Fig. 2). In both devices, the
ACF was integrated onto a porous subchondral bone region
(SBR) formed from D, DeL, L-polylactic acid. Described by
the authors as a ‘‘macrostructure,’’ this same subchondral
bone scaffold has been investigated previously as a carrier
of bone morphogenetic proteins for bone formation24e30.
Suspended within the interstices of the bone region matrix
was a velour of HY. Referred to here as a ‘‘microstructure,’’
the design purpose of the HY was to add biologic functions
such as chemotaxis and signal initiating angiogenesis, and
promote uniform distribution of growth factors31.
Fig. 1. Scanning micrograph of ACF/SBR where the ACF is
composed of HYeCT-polyelectrolytic complex, original magniﬁca-
tion 50!. In its dry form shown here, the HYeCT-PEC fabric is an
open-cell matrix.Materials and methods
Scaffolds were implanted into osteochondral defects
created in the rabbit medial femoral condyle for 24 weeks
and compared to untreated controls (shams). All surgical
sites were assessed for quality of repair tissue utilizing
a modiﬁed O’Driscoll histologic scoring (Fig. 3).
ANIMAL MODEL
Eighteen skeletally mature (nine months old) female New
Zealand White rabbits (35 knees) were used for this study.
The study protocol was approved by the Institutional Animal
Care and Use Committees (IACUC).
TEST ARTICLES
Subchondral bone region (SBR)
The SBR of the systems consisted of a D, DeL, L-polylactic
acid (PLA) (MwZ 300 kDa) macrostructure possessed of
an interconnected, porous architecture simulating that of
cancellous bone (PTM Porous Tissue Matrix: Kensey
Nash Corporation, Exton, Pennsylvania). Invested within
the interstices of the SBR macrostructure was a hyaluronan
microstructure (a velour suspended within the pores of the
PTM) (Life Core Biomedical Inc., Chaska, Minnesota) at an
initial molecular weight of 1680 kDa and a concentration of
10 mg/cc of macrostructure void volume. The SBR was
fabricated to have dimensions of approximately 3.0 mm
diameter! 2.0 mm height, apparent density of approxi-
mately 0.1 g/cc and an average pore size of 150e250 mm
(pores are generated via freeze drying). Void volume for this
region of 14 ml was determined by helium pycnometry.
When implanted subcutaneously in rabbits, the PTM is fully
degraded in 5e9 months.
With the exception of the critical location at the frontier
between regions, the material of the SBR was rendered
hydrophilic during fabrication. The processing allowed the
hyaluronan to be uniformly distributed through the SBR
region creating a hydrophilic environment; however, the
hyaluronan was not deposited at the interface of the
SBReACF, thus creating a hydrophobic region. The ACFs
were attached to the subchondral bone region creating an
interface that functioned as a hydrophobic impedance to
ﬂuids, while allowing cell migration across its frontier. Fig. 4
illustrates this compartmentalization in vitro, in the absence
Fig. 2. Scanning micrograph of ACF/SBR where the ACF is
composed of type I collagen, processed into a 3-D malleable
substratum, original magniﬁcation 20!.
800 S. R. Frenkel et al.: Regeneration of articular cartilageFig. 3. Modiﬁcation of the O’Driscoll histological scoring scale for evaluation of regenerated cartilage and bone.of compressive and shear stresses. Unlike a purely physical
membrane, this region has interstices that allow migration
of potential repair cells between the bone and cartilage
regions but due to its hydrophobic nature, discourages
ﬂuids such as blood from traversing its frontier.
Articular cartilage fabric I (ACF I)
Hyaluronan at a molecular weight of 1680 kDa (Life Core
Biomedical, Chaska, Minnesota) was reacted with chitosan
(molecular weight of 950 kDa; Vanson/HaloSource Red-
mond, Washington) as previously described32. The result-
ing HYeCT-PEC precipitate formed a malleable hydrogel,
capable of retaining its size and shape after being removedfrom its container, and press ﬁt onto the PTM. A lyophilized
HYeCT-PEC with a concentration of 10%e12% (w/v) was
used as the articular cartilage fabric. Individual cylinders of
the combined ACF and SBR measuring approximately
3.0 mm diameter! 3.0 mm height were cored from bulk
devices.
Articular cartilage fabric II (ACF II)
The ACF was composed of a unique ﬁbrous, bovine hide
derived, collagen matrix (P1076 Collagen: Kensey Nash
Corporation, Exton, Pennsylvania). The scaffold has an
overall collagen ﬁbrillar architecture that has been
preserved from the original harvested connective tissue,
801Osteoarthritis and Cartilage Vol. 13, No. 9Fig. 4. Demonstration of boneecartilage interface functioning as a hydrophobic region to ﬂuids. Left to right panels shows colored ﬂuids being
loaded into the ACF and bone compartments of the PEC device; ﬁnal panel demonstrates that material loaded into one compartment does not
cross into the other.while maintaining an open porous structure (average pore
size approximately 61.7 mm) that has been demonstrated to
be conducive to inﬁltration, attachment, and proliferation of
various cell types. When implanted subcutaneously in
rabbits, the collagen is fully degraded within 30 days. The
collagen was press ﬁtted to the PTM foam and lyophilized as
bulk devices. The combined ACF and SBR were cored from
the bulk device to have approximate dimensions of 3.0 mm
diameter! 2.8 mm height. The porosity of the interface
between the two layers was maintained and under SEM
analysis found to have pores in the order of 90 mm (Fig. 2).
Sterilization
Devices employing ACF I (HYeCT-PEC) were sterilized
by exposure to 140 min of hydrogeneoxygen gas plasma
(AbTox Inc., Mundelein, Illinois) while devices utilizing ACF
II (type I collagen) were sterilized by exposure to a minimum
of 25 kGy gamma irradiation. Post-sterilization analytic
chemistry for subchondral bone components of ACF I
materials revealed no change in weight average molecular
weight for the polylactic acid macrostructure while the
hyaluronan microstructure was reduced to a weight average
molecular weight of 252 kDa. Post-sterilization molecular
weight determinations for subchondral bone components of
ACF II revealed substantial reductions for both the
polylactic acid structural polymer (MwZ 135 kDa) and the
hyaluronan microstructure (MwZ 90 kDa).
Surgical procedure
The medial femoral condyle was exposed through
a parapatellar, longitudinal incision, and a lateral sub-
luxation of the patella. Osteochondral defects (3.0 mm
diameter! 2.8 mm depth) were created under irrigation by
custom-designed, hand-operated coring tools on the medial
femoral condyle. The devices were created to be an exact
ﬁt to the osteochondral defects created. For the PEC ACF
devices, NZ 11; for the collagen ACF devices, NZ 12.
Some specimens underwent defect creation, but received
no implant; these formed the sham group (NZ 12). Each
device was initially wetted with sterile saline prior to
implantation. Therefore, with the devices made to exact
dimensions and the natural tendency of the polymer to
swell, the device would lock itself within the defect area.
After placement of the implant, the patella was reduced, andthe wound closed in layers. Postoperatively, rabbits were
left uncasted and allowed free cage movement upon
awakening. Additionally, Buprenorphine (0.01e0.05 mg/kg)
was given intermuscularly or subcutaneously every 6e12 h
as needed beginning 4 h postoperatively and a fentanyl
patch as needed.
Gross examination
Distal femurs were harvested at 24 weeks. Visually
acceptable repairs were noted as smooth, ﬁrm repair tissue
that ﬁlled the defects. The knee was assessed for
osteophyte formation, ﬁbrillation and ﬁssures. Specimens
were ﬁxed in 10% buffered formalin.
Histological preparation
Experimental wound beds having at least 10 mm of
contiguous host bone and cartilage were gently excised.
Each specimen was decalciﬁed in EDTA and sectioned
longitudinally through the center of the defect. Specimens
were stained with hematoxylin and eosin, and with
Safranin-O to assess glycosaminoglycan (GAG) content
and distribution.
Immunohistochemistry preparation
In separate sections, the presence of type II collagen was
detected via immunohistochemistry using anti-type II
collagen antibody (University of Iowa’s Hybridoma Bank,
Iowa City, Iowa (Cat. # 11-116B3)). Immunohistochemistry
images were acquired using a Spot RT digital camera
(Diagnostic Instruments, Inc., Sterling Heights, Michigan).
Histological evaluation
Histological specimens were evaluated using a 27-point
modiﬁed O’Driscoll33 scoring system. Parameters included:
percentage of hyaline- or articular-appearing repair (evalu-
ated histomorphometrically as previously described34),
structural characteristics, freedom from cellular changes of
degeneration, freedom from degenerative changes in
adjacent cartilage, reconstitution of subchondral bone,
repair of tidemark, and Safranin-O staining. Hyaline-like
appearance was judged by comparison with normal,
unoperated host tissue, with respect to the type and density
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these cells. Separately, presence or absence of immunos-
taining for type II collagen was noted. Two observers,
blinded to treatment, performed the evaluations indepen-
dently.
STATISTICAL ANALYSIS
The data was analyzed using Stata 6.0 (StataCorp.,
College Station, Texas). All results represented the means
and standard deviations of their respective groups. Signif-
icance was calculated using a one-tailed Student’s t-test
with unequal variances between groups (P! 0.05).
Results
Visual inspection of the femoral condyle revealed
a smooth surface topography for the majority of the joints
implanted with either device. These surfaces were absent of
inﬂammation, degenerative changes (ﬁbrillation, ﬁssures or
osteophytes), intraarticular adhesions, meniscal damage,
and ligament damage. The repair tissue presented with
a lighter pinkish-white coloration than the surrounding host
tissue, with the majority of defects having better than a 90%
ﬁll of the defect site.
At 24 weeks, PEC composite devices induced a signiﬁ-
cantly better repair (P! 0.05) than untreated shams.
Based upon the modiﬁed O’Driscoll scoring system, the
collagen devices resulted in a quality of repair nearly equal
to that of the PEC group, although its mean repair score
(19.1G 4.2) did not differ signiﬁcantly from that of the PEC
group (20.4G 3.7) or the shams (16.5G 6.3) (please see
Table I for scores of each parameter).
Filler tissue in the sham defects often showed surface
ﬁbrillation and discontinuity with host bone and cartilage
[Fig. 5(A)]. Chondrocyte clusters were apparent in the repair
and at the host interface, with absence of Safranin-O stain
in the ﬁller tissue and loss of GAG in the adjacent host
cartilage. Several PEC and collagen specimens also
demonstrated a partial absence of GAG. However, a co-
lumnar arrangement of chondrocytes [Fig. 5(B)] and good
host-repair integration [Figs. 5(B and C)] were characteristic
of both types of implanted specimens.
Histology scored in accordance with the modiﬁed
O’Driscoll scoring system provided numerical values for
each group (Table I). The degree of bonding of repair tissueto the native cartilage and to the subchondral bone was
greatest with the use of PEC devices, as were the structural
integrity of the regenerated cartilage and the reconstitution
of the subchondral bone. For all the above parameters, the
performance of the collagen devices was similar to that of
the PEC implants, and was better than that of the untreated
shams. The percentage of hyaline-like cartilage in the repair
tissue was highest with collagen implants. In all three
groups, some specimens contained persistent cartilage in
the subchondral region [Fig. 5(D)]. It is likely that this
cartilage will continue to remodel into bone over time.
Immunohistochemistry images stained for type II colla-
gen were evaluated histomorphometrically34 as area
percent of repair tissue. At 24 weeks, there was no
statistically signiﬁcant difference between experimental
specimens and shams. However, there was a numerical
trend favoring wounds treated with either collagen or
HYeCT-PEC formulations. The tissues in device-treated
sites stained positive for both type II collagen and GAG.
Comparison of tissues that stained positive for both type II
collagen and GAG within the same specimen revealed that
Safranin-O positive tissues lacked the usual association
with type II collagen typically seen in normal hyaline
cartilage (Fig. 6).
Discussion
In the past 10e15 years, a variety of monophasic
implants were tested in focal cartilage lesions. A seminal
study by Hunziker and Rosenberg demonstrated that
synovial cells could be recruited to migrate into cartilage
defects and participate in their repair17. The defects were
implanted with a ﬁbrin clot containing a mitogenic growth
factor; mesenchymal cells extending from the synovial
membrane across the superﬁcial tangential zone of normal
articular cartilage ﬁlled the defect. At 48 weeks, the defect
was entirely ﬁlled with ﬁbrous connective tissue.
The present study did not include treatment with a mono-
phasic implant; however, we have examined an open-cell
polylactic acid (OPLA) device in earlier studies 7,11. Chu
et al. and Coutts et al. described studies of up to 1 year’s
duration, in which they treated a 3.7 mm! 5.0 mm deep
osteochondral defect in the rabbit femoral condyle with
a monophasic OPLA cylinder alone or a similar cylinder
covered with a periosteal graft sutured to the synovial
surface of the cylinder with the cambium layer facing the
joint space11,35. The OPLA structure employed in thoseTable I
Cartilage repair histological scores
Characteristic (maximum score) PEC Collagen Sham
Mean N (nZ 11) SD Mean N (nZ 12) SD Mean N (nZ 12) SD
Percent hyaline cartilage (8) 7.5 11 0.9 7.5 12 1.2 5.8 12 2.6
Surface regularity (2) 1.3 11 0.6 1.0 12 0.5 0.8 12 0.8
Structural integrity (2) 1.2 11 0.7 1.2 12 0.7 0.7 12 0.8
Thickness (2) 1.1 11 0.8 1.0 12 0.5 1.2 12 0.6
Bonding to adjacent cartilage (2) 1.5 11 0.5 1.4 12 0.8 1.2 12 0.8
Freedom from cellular changes of degeneration 0.8 11 0.8 1.2 12 0.6 0.7 12 0.7
Freedom from degenerative changes in adjacent cartilage (3) 1.9 11 0.6 1.7 12 0.9 2.0 12 0.7
Reconstitution of subchondral bone (2) 2.0 11 0.2 1.9 12 0.3 1.7 12 0.5
Bonding of repair cartilage to de novo subchondral bone (2) 1.9 11 0.2 1.8 12 0.6 1.6 12 0.7
Safranin-O staining (2) 1.2 11 0.9 0.4 12 0.7 0.8 12 0.9
Average total (27) 20.4* 11 3.7 19.1 12 4.2 16.5 12 6.3
*PEC is signiﬁcantly different from shams, P! 0.05.
803Osteoarthritis and Cartilage Vol. 13, No. 9Fig. 5. Repair at 24 weeks postoperatively. Black bars represent border of defect. Safranin-O stain,!40. (A) Sham. Note ﬁbrillation, clusters,
and lack of integration. (B) Collagen ACF. Columnar chondrocyte architecture, good integration, and positive Safranin-O staining are evident.
(C) PEC ACF. Some surface ﬁbrillation and loss of stain are present, along with well-integrated regenerated and excellent bone reconstitution.
(D) PEC ACF. Note persistent cartilage in subchondral bone region; however, repair is contiguous with host and appears hyaline-like.studies is identical to that used as the SBR in the current
study. OPLA served as a porous scaffolding for cellular
migration and attachment with the subsequent formation of
new cartilage with extracellular matrix. Although mechanical
properties and type II collagen content approached normal
values, the histological appearance of the regenerate was
not that of a normal articular surface. GAG content was low
at all time points.
In a subsequent study, our group tested a construct in
which the macrostructure for both articular cartilage and
subchondral bone regions was composed of OPLA, but
the 3-D architectures were customized to resemble the
gross histological pattern of each tissue region36. Hyalur-
onic acid velour served as the microstructure for the
subchondral bone region. The subchondral bone region
and articular cartilage regions were charged with rhBMP-2
at two different concentrations (ACFZ 100 mg/100 mL;
Subchondral bone regionZ 5.0 mg/100 mL). Histology from
our 6-week study (unpublished data) demonstrated that we
had produced excellent subchondral bone within the defect,
but had also generated vertically oriented columns of bone
in the articular cartilage portion of the device (Fig. 7).
The current multiphasic design includes articular cartilage
fabrics that conform to principles of cellular tensegrity
demanded by chondrocytes while contributing to biochem-
ical support of the chondrocyte phenotype. Collagen type I
provides a malleable cell culture substratum for the ACF of
the ﬁrst device. The second device’s ACF, composed of
a HYeCT-PEC, is likely to supply both mechanical and
biochemical signals supporting the chondrocyte phenotype.
With or without a bone morphogenetic protein, type I
collagen has been shown to support hyaline-like repair of
articular cartilage defects for sustained periods of
time10,37e40. Both hyaluronan and chitosan, studied in-
dividually, have been found to support the chondrocyte
phenotype41e47. Additionally, Cancedda and co-workers
have demonstrated that a malleable substratum is required
for support of the chondrocyte phenotype48. Combining
hyaluronan and chitosan through the mechanism of
electrostatic attraction produced a polyelectrolytic com-
plex possessed of sufﬁcient mechanical and hydrologicFig. 6. Micrographs of collagen ACF device, !40. (A). Immuno-
histochemical stain for type II collagen demonstrating collagen
localized to the synovial surface of the regenerated articular
cartilage. (B) Safranin-O positive material localized to deeper
regions of regenerated articular cartilage.
804 S. R. Frenkel et al.: Regeneration of articular cartilageFig. 7. Repair specimen from medial femoral condyle, from authors’ 6-week study (unpublished). Both articular cartilage and subchondral bone
regions are composed of OPLA, with 3-D architectures customized to resemble the gross histological pattern of each tissue region36.
Hyaluronic acid velour served as the microstructure for the subchondral bone region. Note vertical columns of bone formed in ACF in response
to the geometry and rigid physical properties of the substratum in that region, !40.properties to qualify it as a malleable, in vivo, cell culture
environment favoring the chondrocyte phenotype.
Data reported here demonstrate that both the PEC and
type I collagen multiphasic implants are capable of de-
veloping hyaline-appearing tissue maintained at 24 weeks
postoperatively. An important feature of both devices is their
ability to remain at the site of implantation without additional
ﬁxation methods. This results from an interference ﬁt
designed into the device coring tool system that allows for
a frictional ﬁt between the implant and surrounding tissue.
Preliminary data using these devices in 6 mm diameter
defects in goats indicate these devices are also retained in
larger surgical sites, overcoming a major impediment seen
with many other cartilage repair devices and strategies.
Both devices were able to address the difﬁcult task of
maintaining speciﬁc cell phenotypes, per region, over time.
The design of these constructs allowed rapid regeneration
of subchondral bone and consistent generation of a com-
petent tidemark. Furthermore, cells populating the articular
cartilage region of the devices differentiated to the
chondrocyte phenotype and produced biologic markers
unique to the chondrocyte phenotype without beneﬁt of
exogenous morphogens or growth factors.
Customization of a micro- or bioenvironment has been
reported, wherein a 3-D architecture may support cell
growth49. Some two-phase or bilayer techniques have been
created which include regions for both cartilage and bone
regeneration8,9,50. However, these materials do not have
a distinct partition or region to separate the two layers in
order to prevent blood vessels from invading the cartilag-
inous microenvironment, rendering it unfavorable to chon-
droneogenesis. Others have investigated whether
physically blocking angiogenic activities and osteogenic
processes can be accomplished through the use of an
occluding membrane51. Nondiscriminatory in effect, this
structural region has the disadvantage of also preventingthe passage of reparative cells from underlying undifferen-
tiated marrow mesenchymal cell sources52, allowing pop-
ulation of the implant only by cells from other sources.
Chemical impedance of blood vessels and new bone
using an antiangiogenic factor within the chondrogenic
repair matrix has also been explored53. Referred to as
a ‘‘functional barrier’’ by Hunziker et al.53 it is not a physical
barrier, as a partition does not exist between the cartilage
and bone regions. Rather, the drug creates a two-phased
material with the superﬁcial region being a cartilage-
favoring compartment. The success of this work suggested
to the authors that a multiphasic device might be
appropriate for osteochondral repair.
The multiphasic implants employed in our study contain
a unique physicochemical region partitioning the cartilage
and subchondral bone tissue-speciﬁc bioenvironments.
Unlike a purely physical membrane, the region has
interstices that allow migration of potential repair cells
between the bone and cartilage regions but due to its
hydrophobic nature, discourages ﬂuids such as blood from
traversing its frontier. Further, since the region is a conse-
quence of hydrophobic surface chemistry, the region
does not have a half-life that would attend a chemical
barrier. This region, while effective at preventing trespass of
ﬂuids, does not have properties that would exclude cell
types. Fig. 8 shows the presence of mesenchymal cells
immediately subjacent to Safranin-O-positive staining chon-
drocytes in the repair, suggesting the origin of these cells
from the marrow. Pre-osteoblastic or mesenchymal cells
that have started down the osteogenic pathway located
in the subchondral bone region (SBR) may cross the
physicochemical region into the articular cartilage fabric
(ACF) of the device. Additionally, it has been demonstrated
by others that cells from the synovial membrane17,54,
synovial ﬂuid55, and the articular cartilage surface itself56
may populate the ACF. In the malleable substrate of the
805Osteoarthritis and Cartilage Vol. 13, No. 9Fig. 8. Micrograph of PEC ACF device,!40. Central region is Safranin-O positive. Inset: note the presence of mesenchymal cells immediately
subjacent to Safranin-O-positive staining chondrocytes in the repair, suggesting that cells in this area may have migrated into the HYeCT-PEC
fabric from the marrow.ACF, these precursor cells will no longer be exposed to the
extracellular and biomechanical prompts needed for oste-
ogenic (or other non-chondrocytic cell type) lineage pro-
gression20. Importantly, the physicochemical partition will
discourage vascularization of the ACF by preventing ﬂuid
blood from entering the region. In the absence of blood
vessels, bone formation is adversely fated21e23. Corre-
spondingly, any chondrocytes that migrate into the SBR
region will receive biochemical and biomechanical signals
that favor osteogenic differentiation. At this point the cell
may die, or these different cues may initiate profound
changes in the morphology and biosynthetic activity of the
cells causing them to transdifferentiate toward the osteo-
blastic phenotype18,19. The nature of the physicochemical
region between the cartilage and bone compartments
makes these devices ideal for delivery of different growth
factors or drugs in each compartment, or different doses of
the same factor. It also renders these devices excellent
vehicles for chondrocyte or stem cell transplantation.
Previous studies using a collagen bilayer57, with neither
cells nor growth factors added to the materials, reported 24
week results. The repair was integrated into the native
tissue and appeared to have improved survival over time as
compared to empty defects, but contained little normal-
appearing hyaline cartilage, with irregular surfaces. The
results of the present study show that the two devices are
retained at the implantation site, and provide a favorable
environment for formation of hyaline-appearing repair
tissues sustained over 24 weeks. The implants are well
tolerated by surrounding tissues, and resorb with no ill
effects upon the remodeling host.
Dissociation of GAG from type II collagen at 24 weeks
was an unexpected ﬁnding. In vitro studies of articular
cartilage explants have shown that lysis of GAG precedes
catabolism of type II collagen in the progression of
osteoarthritis58e60. To be consistent with these previous
reports, the ﬁndings should have revealed type II collagen
present in the same regions demonstrating Safranin-O
positive GAG. Instead, type II collagen was reliablyrestricted to one location while GAG was partitioned within
a disconnected space, each remaining independent of the
other. It is possible that the apparent dissociation is an
artifact related to epitope exposure or integrity within the
tissue.
While this ﬁnding does not correspond precisely to prior
observations, these results do offer a basis for speculation.
Both experimental formulations, and to a lesser extent the
untreated sham specimens, produced promising but imper-
fect hyaline-like repair tissue. It is conceivable that the cells
populating these tissues are newly differentiated cells that
have not propagated through the repaired cartilage and, at
24 weeks, are in the process of remodeling the repair site.
Our present observation may represent an imbalance in
regeneration or degradation of GAG and type II collagen.
What is clear is that cells populating both experimental
formulations are producing biologic markers unique to
the chondrocyte phenotype. Investing the devices with
chondrocytes or pluripotent cells at high concentration and/
or appropriate morphogens and growth factors is likely to
produce self-sustaining hyaline-like cartilage repair tissues.
Ongoing research is currently examining the ability of the
implants to serve as delivery devices for cells and growth
factors.
While the results obtained in this study are promising, the
potential for resurfacing larger defects of articular cartilage
must be examined before discussing whether the implant
has clinical application in humans. Investigation of later time
points will also be necessary to assess the long-term
survival of the repair.
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